Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
Telbivudine has been reported to be more effective than lamivudine. However, because of the resistance rate to telbivudine (TLV), the current guidelines recommend entecavir (ETV) or tenofovir (TNV) as the first-line therapy for chronic hepatitis B. We investigated the short term virologic efficacy o...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/181065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552787433488384 |
|---|---|
| author | Young Woon Kim Jung Hyun Kwon Eun Chung Sung Won Lee Jong-yul Lee Jeong Won Jang Kyu Won Chung Soon Woo Nam |
| author_facet | Young Woon Kim Jung Hyun Kwon Eun Chung Sung Won Lee Jong-yul Lee Jeong Won Jang Kyu Won Chung Soon Woo Nam |
| author_sort | Young Woon Kim |
| collection | DOAJ |
| description | Telbivudine has been reported to be more effective than lamivudine. However, because of the resistance rate to telbivudine (TLV), the current guidelines recommend entecavir (ETV) or tenofovir (TNV) as the first-line therapy for chronic hepatitis B. We investigated the short term virologic efficacy of TLV in comparison with ETV as the first-line agent of HBV suppression in HBV-related advanced HCC patients. A total of 86 consecutive patients with HBV-related HCC for whom antiviral treatment was initiated in Incheon St. Mary’s Hospital between 2010 and 2013 were analyzed. Virologic responses were investigated on the 4th, 12th, and 24th weeks of the antiviral therapies. In patients with advanced TNM stage cancer (stage 3 or 4) and poor liver function (Child-Pugh class B or C), the virologic response rates at weeks 12 and 24 were 25% (1/4) and 42.8% (3/7) in the TLV group and 33.3% (1/3) and 33.3% (1/3) in the ETV group, respectively (P=0.424, P=0.800). The short term efficacy of TLV was similar to that of ETV. Since TLV is highly cost-effective, it should be considered as a first-line antiviral agent in patients with advanced HCC, poor liver function, and short life expectancies. |
| format | Article |
| id | doaj-art-882864c635bb4e5eb94d8112058fb62a |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-882864c635bb4e5eb94d8112058fb62a2025-02-03T05:57:49ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/181065181065Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular CarcinomaYoung Woon Kim0Jung Hyun Kwon1Eun Chung2Sung Won Lee3Jong-yul Lee4Jeong Won Jang5Kyu Won Chung6Soon Woo Nam7Catholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaDepartment of Internal Medicine, Incheon St. Mary’s Hospital, Catholic University of Korea, Bupyeong 6-dong, Bupyeong-gu, Incheon 403-720, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaCatholic Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaTelbivudine has been reported to be more effective than lamivudine. However, because of the resistance rate to telbivudine (TLV), the current guidelines recommend entecavir (ETV) or tenofovir (TNV) as the first-line therapy for chronic hepatitis B. We investigated the short term virologic efficacy of TLV in comparison with ETV as the first-line agent of HBV suppression in HBV-related advanced HCC patients. A total of 86 consecutive patients with HBV-related HCC for whom antiviral treatment was initiated in Incheon St. Mary’s Hospital between 2010 and 2013 were analyzed. Virologic responses were investigated on the 4th, 12th, and 24th weeks of the antiviral therapies. In patients with advanced TNM stage cancer (stage 3 or 4) and poor liver function (Child-Pugh class B or C), the virologic response rates at weeks 12 and 24 were 25% (1/4) and 42.8% (3/7) in the TLV group and 33.3% (1/3) and 33.3% (1/3) in the ETV group, respectively (P=0.424, P=0.800). The short term efficacy of TLV was similar to that of ETV. Since TLV is highly cost-effective, it should be considered as a first-line antiviral agent in patients with advanced HCC, poor liver function, and short life expectancies.http://dx.doi.org/10.1155/2015/181065 |
| spellingShingle | Young Woon Kim Jung Hyun Kwon Eun Chung Sung Won Lee Jong-yul Lee Jeong Won Jang Kyu Won Chung Soon Woo Nam Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma Gastroenterology Research and Practice |
| title | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| title_full | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| title_fullStr | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| title_full_unstemmed | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| title_short | Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma |
| title_sort | short term virologic efficacies of telbivudine versus entecavir against hepatitis b related hepatocellular carcinoma |
| url | http://dx.doi.org/10.1155/2015/181065 |
| work_keys_str_mv | AT youngwoonkim shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT junghyunkwon shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT eunchung shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT sungwonlee shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT jongyullee shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT jeongwonjang shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT kyuwonchung shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma AT soonwoonam shorttermvirologicefficaciesoftelbivudineversusentecaviragainsthepatitisbrelatedhepatocellularcarcinoma |